Straits Times Index
3,304.00 +2.22 (+0.07%) S&P 500
5,487.03 +13.80 (+0.25%) Dow
38,834.86 +56.76 (+0.15%) Nasdaq
17,862.23 +5.21 (+0.03%) Bitcoin USD
64,918.59 +484.88 (+0.75%) CMC Crypto 200
1,383.53 +45.78 (+3.42%)
Gain Therapeutics, Inc. (GANX)
After hours:
| Previous close | 1.3200 |
| Open | 1.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.2600 - 1.3600 |
| 52-week range | 1.2300 - 5.3300 |
| Volume | |
| Avg. volume | 199,325 |
| Market cap | 32.216M |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5000 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireGain Therapeutics Announces Pricing of $11.0 Million Public Offering
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their o
- GlobeNewswire
Gain Therapeutics Announces Proposed Public Offering
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. All of the securities are b
- GlobeNewswire
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s diseaseBETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data on GT-02287 has been accepted for presentation
